Assessing Chemours (CC) Valuation After A Strong Multi‑Period Share Price Run
Chemours (CC) has seen significant stock price appreciation recently, with shares up over 24% in the last month and over 115% year-to-date. Despite this surge and a current price of $26.34 against an analyst target of $22.67, Simply Wall St's analysis suggests the stock is overvalued, with a fair value of $16.33, primarily due to future earnings potential and lingering legal risks. However, another view based on multiples suggests a 55.3% discount to intrinsic value, highlighting a split in valuation perspectives due to recent returns and unresolved risks.
https://simplywall.st/stocks/us/materials/nyse-cc/chemours/news/assessing-chemours-cc-valuation-after-a-strong-multiperiod-s